Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Partnership Targets Diabetes Drug Implant

by Michael McCoy
November 17, 2014 | A version of this story appeared in Volume 92, Issue 46

Boston-based Intarcia Therapeutics has signed up France’s Servier as a partner to develop the diabetes treatment ITCA 650 outside the U.S. and Japan. ITCA 650 is a matchstick-sized implant that delivers exenatide, a peptide that is the active ingredient in the diabetes drug Byetta. Intarcia, which calls itself the highest-valued private biotech company in history, will get $171 million up front and three early-stage regulatory milestones totaling $230 million. ITCA 650 is now in Phase III clinical trials for the treatment of type 2 diabetes.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.